MX2022006472A - Formulacion pediatrica de liberacion inmediata del abridor de canales de potasio ezogabina. - Google Patents

Formulacion pediatrica de liberacion inmediata del abridor de canales de potasio ezogabina.

Info

Publication number
MX2022006472A
MX2022006472A MX2022006472A MX2022006472A MX2022006472A MX 2022006472 A MX2022006472 A MX 2022006472A MX 2022006472 A MX2022006472 A MX 2022006472A MX 2022006472 A MX2022006472 A MX 2022006472A MX 2022006472 A MX2022006472 A MX 2022006472A
Authority
MX
Mexico
Prior art keywords
ezogabine
immediate
pediatric
release formulation
potassium channel
Prior art date
Application number
MX2022006472A
Other languages
English (en)
Inventor
Jean-Jacques Alexandre Cadieux
Matthew David Tandy
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MX2022006472A publication Critical patent/MX2022006472A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulga en la presente formulaciones farmacéuticas orales de liberación inmediata que comprende una cantidad terapéuticamente efectiva de ezogabina y uno o más excipientes farmacéuticamente aceptables para uso en el tratamiento de la epilepsia y/o del trastorno de crisis epilépticas en un mamífero, preferentemente un humano, más preferentemente un niño. También se divulgan métodos para usar y hacer las formulaciones farmacéuticas orales de liberación inmediata.
MX2022006472A 2019-12-02 2020-12-02 Formulacion pediatrica de liberacion inmediata del abridor de canales de potasio ezogabina. MX2022006472A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962942579P 2019-12-02 2019-12-02
PCT/US2020/062918 WO2021113381A1 (en) 2019-12-02 2020-12-02 Pediatric immediate-release formulation of the potassium channel opener ezogabine

Publications (1)

Publication Number Publication Date
MX2022006472A true MX2022006472A (es) 2022-09-09

Family

ID=74181279

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006472A MX2022006472A (es) 2019-12-02 2020-12-02 Formulacion pediatrica de liberacion inmediata del abridor de canales de potasio ezogabina.

Country Status (15)

Country Link
US (1) US20210169839A1 (es)
EP (1) EP4069201A1 (es)
JP (1) JP2023504154A (es)
KR (1) KR20220108116A (es)
CN (1) CN114760990A (es)
AU (1) AU2020395158A1 (es)
BR (1) BR112022010458A2 (es)
CA (1) CA3162907A1 (es)
CL (1) CL2022001426A1 (es)
CO (1) CO2022007345A2 (es)
CR (1) CR20220313A (es)
IL (1) IL293352A (es)
MX (1) MX2022006472A (es)
PE (1) PE20221396A1 (es)
WO (1) WO2021113381A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US20100120906A1 (en) * 2008-07-18 2010-05-13 Valeant Pharmaceuticals International Modified release formulation and methods of use
DE102009013613A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
DE102009013612A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
WO2011039369A2 (en) * 2009-10-02 2011-04-07 Medichem S.A. Amorphous forms of a 2-amino-4-(4-fluorobenzylamino)phenylcarbamate derivative
SG181827A1 (en) * 2010-01-20 2012-07-30 Glaxo Group Ltd Novel retigabine composition
US20130267590A1 (en) * 2011-09-13 2013-10-10 Dr. Reddy's Laboratories Limited Retigabine compositions

Also Published As

Publication number Publication date
PE20221396A1 (es) 2022-09-14
KR20220108116A (ko) 2022-08-02
CL2022001426A1 (es) 2023-03-24
IL293352A (en) 2022-07-01
JP2023504154A (ja) 2023-02-01
WO2021113381A1 (en) 2021-06-10
CR20220313A (es) 2022-10-31
CO2022007345A2 (es) 2022-06-10
CN114760990A (zh) 2022-07-15
US20210169839A1 (en) 2021-06-10
BR112022010458A2 (pt) 2022-09-06
EP4069201A1 (en) 2022-10-12
AU2020395158A1 (en) 2022-06-23
CA3162907A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
MX2022006258A (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
CR20220316A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
IL189546A0 (en) Therapy for the treatment of disease
MX2019001321A (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
MX2021002321A (es) Nuevos metodos.
MX2018008021A (es) Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
MX2022000143A (es) Metodos novedosos.
MX2021002322A (es) Nuevos metodos.
MX2023011326A (es) Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.
SA519410993B1 (ar) النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية
NZ767378A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
WO2018140792A3 (en) Neurotrophin mutants for treating hearing loss and other otic disorders
MX2022006472A (es) Formulacion pediatrica de liberacion inmediata del abridor de canales de potasio ezogabina.
EP3972432A4 (en) PHARMACEUTICAL FORMULATIONS AND METHODS FOR DELIVERING A THERAPEUTIC, DIAGNOSTIC OR CONTRAST AGENT TO CD206
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
EP4028095A4 (en) RESPIRATORY DISORDER THERAPY SYSTEM AND PATIENT INTERFACE AND HEADGEAR FOR USE IN THE SAME